KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Switching from Dupilumab to Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis After Inadequate Response to Dupilumab: Efficacy and Safety Results from Period 2 of Phase 3b/4 Study (LEVEL UP).

Christopher G Bunick, Nina Magnolo, Angela Moore, Masatoshi Abe, Xinghua Gao, Charles Lynde, Nadia Ibrahim, Gweneth Levy, Brian M Calimlim, Xiaoqiang Wu, Yolanda Armendariz, Ayman Grada, Kilian Eyerich

Am J Clin Dermatol 27(2) 391-399

PMID41533220
PMCIDPMC13033017
DOI10.1007/s40257-025-01003-0
发表日期2026-01-14
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:Fig. 1:CONSORT/入组流程图;Fig. 2:非 KM 图。
摘要

摘要

BACKGROUND: Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by intense itch and eczematous skin lesions. Upadacitinib, a selective oral Janus kinase inhibitor, and dupilumab, a monoclonal antibody, are both approved treatments for moderate-to-severe AD. In period 1 of the LEVEL UP phase 3b/4 head-to-head study, upadacitinib-treated patients demonstrated higher simultaneous achievement of near complete skin clearance and little to no itch compared with dupilumab after 16 weeks of treatment in adults and adolescents with moderate-to-severe AD. OBJECTIVE: The objective of period 2 of the LEVEL UP study was to assess the efficacy and safety of switching from dupilumab to upadacitinib in patients with inadequate response to dupilumab. METHODS: Following period 1 of the LEVEL UP study, patients not achieving ≥ 75% improvement in the Eczema Area and Severity Index (EASI 75) from baseline at week 16 entered an additional 16-week extension phase (period 2). In period 2, patients receiving dupilumab were switched to upadacitinib 15 mg, with the potential to escalate to 30 mg based on clinical response. End points in period 2 included EASI 90, Worst Pruritus Numerical Rating Scale (WP-NRS) 0/1, and simultaneous achievement of both EASI 90 and WP-NRS 0/1 at week 20 and week 32. RESULTS: A total of 208 patients were switched from dupilumab to upadacitinib, entering period 2 of the study. At week 32, response rates for patients who switched were: 79.6%, 58.7%, and 19.9% achieving EASI 75, EASI 90, and EASI 100, respectively; 60.2% achieving Worst Pruritus Numerical Rating Scale improvement ≥ 4 among those with baseline WP-NRS ≥ 4; 37.0% achieving WP-NRS 0/1 among those with baseline WP-NRS > 1; and 26.8% simultaneously achieving EASI 90 and WP-NRS 0/1. Clinically, meaningful outcomes were also observed at week 20. No new safety signals were identified compared with the established safety profile of upadacitinib. CONCLUSIONS: The current findings suggest that switching from dupilumab to upadacitinib may be an effective treatment strategy for patients who do not meet moderate-to-optimal treatment targets with dupilumab. CLINICAL TRIAL REGISTRATION: LEVEL UP (NCT05601882).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Level Up study design. BL, baseline; AD, atopic dermatitis; EASI, Eczema Area and Severity Index; vIGA-AD, Validated Investigators Global Scale for Atopic Dermatitis; BSA, body surface area; WP-NRS, Worst Pruritus Numerical Rating Scale. UPA includes all patients (both 15 mg and 30 mg doses). Target enrollment was 880 patients; numbers reported above reflect the 920 patients randomized
非 KM Figure
Fig. 2Efficacy outcomes for patients at week 20 and week 32 who switched from DUPI to UPA at week 16 (OC, ITT_2 population). EASI, Eczema Area and Severity Index; WP-NRS, Worst Pruritus Numerical Rating Scale. Patients receiving topical rescue were imputed as nonresponders. WP-NRS 0/1 is assessed among patients with WP-NRS > 1 at baseline, WP-NRS reduction (improvement) ≥ 4 (∆WP-NRS ≥ 4) is assessed among patients with Baseline WP-NRS ≥ 4 . Detailed explanations of end points are provided in Table 2
非 KM Figure